Young L S, Stevens P, Ingram J
J Clin Invest. 1975 Oct;56(4):850-61. doi: 10.1172/JCI108164.
Antibodies against the "core" glycolipid of Enterobacteriaceae (2-keto, 3-deoxyoctonate-Lipid A) have been associated with protection against the sequelae of gram-negative rod bacteremia. To investigate the nature of this protection, dogs and rabbits were immunized with purified glycolipid prepared by phenol-chloroform-petroleum ether extraction of the "Re" mutant of Salmonella minnesota 595 and opsonophagocytic and bactericidal tests were carried out using lapine peritoneal granulocytes and serum factors. Whereas 1-4 mug/kg of glycolipid i.v. produced hypotension in dogs and 8 mug/kg i.v. was lethal, a rising dosage schedule of immunization with an average total dose of 1 mg/kg produced striking protection against shock and death against challenge with heterologous organisms. 20 control dogs, given approximately 10(10) live, serum-resistant Escherichia coli 0.85:H9 or Serratia marcescens 03 during a continuous intra-arterial pressure transducer recording, showed a drop in mean systolic pressure from 186 (+/- 6 SE) to 101 (+/- 12 SE) MM Hg and a fall in mean diastolic pressure from 118 (+/- 3 SE) to 64 (+/- 8 SE) mm Hg within 60-120 min. Minor pressure changes (average less than 12% of prechallenge levels) were seen in the same number of immunized dogs. In contrast, no significant difference was noted in the bloodstream clearance of these serum-resistant organisms over a period of 4-6 h between immunized and control dogs. Intravascular clearance was greater in animals immunized with the challenged strain or in glycolipid-immunized animals challenged with highly serum-sensitive E. coli 0.14:K7. Antibody against core glycolipid protected against the hemodynamic sequelae of bacillemia, augmented intravascular clearance of serum-sensitive organisms, and abrogated the pyrogenic response to enteric bacilli, but did not enhance clearance of serum-resistant organisms. Although canine and lapine antiserum against core glycolipid passively protected mice against a heterologous challenge, opsonophagocytic and bactericidal activity was at least 100-fold less than type-specific antiserum.
针对肠杆菌科“核心”糖脂(2-酮基,3-脱氧辛酮酸 - 脂质A)的抗体已被证明与预防革兰氏阴性杆菌血症的后遗症有关。为了研究这种保护作用的本质,用通过苯酚 - 氯仿 - 石油醚提取明尼苏达沙门氏菌595的“Re”突变体制备的纯化糖脂对犬和兔进行免疫,并使用兔腹膜粒细胞和血清因子进行调理吞噬和杀菌试验。静脉注射1 - 4微克/千克的糖脂会使犬出现低血压,静脉注射8微克/千克则会致死,而平均总剂量为1毫克/千克的递增免疫方案能显著保护动物免受休克和异源生物体攻击导致的死亡。在连续动脉内压力传感器记录期间,给20只对照犬注射约10¹⁰个对血清有抗性的活大肠杆菌0.85:H9或粘质沙雷氏菌03,结果显示平均收缩压在60 - 120分钟内从186(±6标准误)毫米汞柱降至101(±12标准误)毫米汞柱,平均舒张压从118(±3标准误)毫米汞柱降至64(±8标准误)毫米汞柱。相同数量的免疫犬仅出现轻微的压力变化(平均小于攻击前水平的12%)。相比之下,在4 - 6小时内,免疫犬和对照犬对这些血清抗性生物体的血液清除率没有显著差异。用攻击菌株免疫的动物或用对血清高度敏感的大肠杆菌0.14:K7攻击的糖脂免疫动物的血管内清除率更高。针对核心糖脂的抗体可预防菌血症的血流动力学后遗症,增强对血清敏感生物体的血管内清除率,并消除对肠道杆菌的发热反应,但不会增强对血清抗性生物体的清除率。尽管犬和兔针对核心糖脂的抗血清能被动保护小鼠免受异源攻击,但其调理吞噬和杀菌活性比型特异性抗血清至少低100倍。